Nombre del producto:2,3-Dichloropyrido[3,4-b]pyrazine

IUPAC Name:2,3-dichloropyrido[3,4-b]pyrazine

CAS:35251-99-1
Fórmula molecular:C7H3Cl2N3
Pureza:95%+
Número de catálogo:CM332598
Peso molecular:200.02

Unidad de embalaje Stock disponible Precio($) Cantidad
CM332598-100mg in stock ȎŢ
CM332598-250mg in stock ǤƓƄ
CM332598-1g in stock ǵŢǵ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :35251-99-1
Fórmula molecular:C7H3Cl2N3
Punto de fusión:-
Código de sonrisas:ClC1=NC2=CN=CC=C2N=C1Cl
Densidad:
Número de catálogo:CM332598
Peso molecular:200.02
Punto de ebullición:
Nº Mdl:MFCD19374272
Almacenamiento:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Pyrazines
Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.
pyrazine,pyrazine price
if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.

Column Infos

CVN424
In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events. Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II. These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products